Histologic and immune characterization of cutaneous immune-related adverse events induced by immune checkpoint inhibitors
Background Although immune checkpoint inhibitors (ICIs) are efficacious, they often cause immune-related adverse events (irAEs), most commonly cutaneous irAEs (CirAEs). The mechanisms underlying CirAEs remain unclear.Methods Attempting to better understand their mechanisms and histology we conducted...
Saved in:
| Main Authors: | Jonathan L Curry, Aung Naing, Joud Hajjar, Cara L Haymaker, Ken Chen, Dzifa Yawa Duose, Anisha B Patel, Omar Pacha, Nejla Ozirmak Lermi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2025-08-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/13/8/e011401.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
T-cell agonists in cancer immunotherapy
by: Gennaro Ciliberto, et al.
Published: (2020-10-01) -
Strategies for improving the management of immune-related adverse events
by: James L Gulley, et al.
Published: (2020-10-01) -
Recommendations for standardizing biopsy acquisition and histological assessment of immune checkpoint inhibitor-associated colitis
by: Brian G Feagan, et al.
Published: (2022-03-01) -
Negative Immune Checkpoint Inhibitors
by: Magda Drewniak-Świtalska, et al.
Published: (2025-05-01) -
Unleashing immunity against oral cancer with immune checkpoint inhibitors
by: Ajay Guru
Published: (2024-06-01)